InvestorsObserver is giving Sorrento Therapeutics Inc (SRNE) an Analyst Rating Rank of 74, meaning SRNE is ranked higher by analysts than 74% of stocks. The average price target for SRNE is $26.666 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating SRNE a Strong Buy today. Find out what this means to you and get the rest of the rankings on SRNE!